PURPOSE: Flavopiridol, a cyclin-dependent kinase inhibitor, has promising clinical activity when combined with chemotherapy. Preclinical data indicate that flavopiridol enhances oxaliplatin- and fluorouracil (5FU)-induced apoptosis in a sequence-dependent manner. EXPERIMENTAL DESIGN: We conducted a phase I trial of flavopiridol + FOLFOX (folinic acid, 5FU, and oxaliplatin) for advanced solid tumors. Flavopiridol was administered every 2 weeks with oxaliplatin before 5FU, based on sequence-dependent growth inhibition. Flavopiridol pharmacokinetics and p53 status were evaluated. RESULTS: Forty-eight patients were treated on study. With dose escalation of oxaliplatin (85 mg/m(2)) and 5FU (2,400 mg/m(2)), dose-limiting toxicities included hyponatremia, thrombocytopenia, and neutropenia. 5FU was subsequently reduced to allow for dose escalation of flavopiridol. Dose-limiting toxicities with escalation of flavopiridol were nausea, vomiting, and neutropenia. The maximum tolerated dose was 70 mg/m(2) flavopiridol, 85 mg/m(2) oxaliplatin, and 1,800 mg/m(2) 5FU continuous infusion over 48 hours. Clinical activity was noted in platinum-refractory germ cell tumors: 3 of 9 (33%) evaluable patients showed a partial response on imaging and 7 of 10 (70%) had a decline in serum tumor markers. Responses were also observed in pancreatic, gastric, and sweat gland tumors. Flavopiridol pharmacokinetics had significant interpatient variability. At the maximum tolerated dose, tumor samples were p53 mutant (>30% positive cells) for responders and p53 wild-type for nonresponders. CONCLUSIONS: Flavopiridol with FOLFOX is a safe and tolerable regimen. Promising clinical activity was seen across tumor types. Encouraging results in the platinum-refractory germ cell tumor population has prompted a phase II trial that is currently open for accrual.
PURPOSE:Flavopiridol, a cyclin-dependent kinase inhibitor, has promising clinical activity when combined with chemotherapy. Preclinical data indicate that flavopiridol enhances oxaliplatin- and fluorouracil (5FU)-induced apoptosis in a sequence-dependent manner. EXPERIMENTAL DESIGN: We conducted a phase I trial of flavopiridol + FOLFOX (folinic acid, 5FU, and oxaliplatin) for advanced solid tumors. Flavopiridol was administered every 2 weeks with oxaliplatin before 5FU, based on sequence-dependent growth inhibition. Flavopiridol pharmacokinetics and p53 status were evaluated. RESULTS: Forty-eight patients were treated on study. With dose escalation of oxaliplatin (85 mg/m(2)) and 5FU (2,400 mg/m(2)), dose-limiting toxicities included hyponatremia, thrombocytopenia, and neutropenia. 5FU was subsequently reduced to allow for dose escalation of flavopiridol. Dose-limiting toxicities with escalation of flavopiridol were nausea, vomiting, and neutropenia. The maximum tolerated dose was 70 mg/m(2) flavopiridol, 85 mg/m(2) oxaliplatin, and 1,800 mg/m(2) 5FU continuous infusion over 48 hours. Clinical activity was noted in platinum-refractory germ cell tumors: 3 of 9 (33%) evaluable patients showed a partial response on imaging and 7 of 10 (70%) had a decline in serum tumor markers. Responses were also observed in pancreatic, gastric, and sweat gland tumors. Flavopiridol pharmacokinetics had significant interpatient variability. At the maximum tolerated dose, tumor samples were p53 mutant (>30% positive cells) for responders and p53 wild-type for nonresponders. CONCLUSIONS:Flavopiridol with FOLFOX is a safe and tolerable regimen. Promising clinical activity was seen across tumor types. Encouraging results in the platinum-refractory germ cell tumor population has prompted a phase II trial that is currently open for accrual.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: C Kollmannsberger; O Rick; H-G Derigs; N Schleucher; P Schöffski; J Beyer; R Schoch; H G Sayer; A Gerl; M Kuczyk; C Spott; L Kanz; C Bokemeyer Journal: J Clin Oncol Date: 2002-04-15 Impact factor: 44.544
Authors: Gary K Schwartz; Eileen O'Reilly; David Ilson; Leonard Saltz; Sunil Sharma; William Tong; Peter Maslak; Maxine Stoltz; Larry Eden; Pam Perkins; Sandra Endres; John Barazzoul; David Spriggs; David Kelsen Journal: J Clin Oncol Date: 2002-04-15 Impact factor: 44.544
Authors: Manish A Shah; Jeremy Kortmansky; Monica Motwani; Marija Drobnjak; Mithat Gonen; Sandy Yi; Amanda Weyerbacher; Carlos Cordon-Cardo; Robert Lefkowitz; Baruch Brenner; Eileen O'Reilly; Leonard Saltz; William Tong; David P Kelsen; Gary K Schwartz Journal: Clin Cancer Res Date: 2005-05-15 Impact factor: 12.531
Authors: A de Gramont; A Figer; M Seymour; M Homerin; A Hmissi; J Cassidy; C Boni; H Cortes-Funes; A Cervantes; G Freyer; D Papamichael; N Le Bail; C Louvet; D Hendler; F de Braud; C Wilson; F Morvan; A Bonetti Journal: J Clin Oncol Date: 2000-08 Impact factor: 44.544
Authors: Bin Jia; Edwin Choy; Gregory Cote; David Harmon; Shunan Ye; Quancheng Kan; Henry Mankin; Francis Hornicek; Zhenfeng Duan Journal: Cancer Lett Date: 2013-09-02 Impact factor: 8.679
Authors: Jason J Luke; David R D'Adamo; Mark A Dickson; Mary Louise Keohan; Richard D Carvajal; Robert G Maki; Elisa de Stanchina; Elgilda Musi; Samuel Singer; Gary K Schwartz Journal: Clin Cancer Res Date: 2012-02-28 Impact factor: 12.531
Authors: Bhuvaneswari Ramaswamy; Mitch A Phelps; Robert Baiocchi; Tanios Bekaii-Saab; Wenjun Ni; Ju-Ping Lai; Anna Wolfson; Mark E Lustberg; Lai Wei; Deidre Wilkins; Angela Campbell; Daria Arbogast; Austin Doyle; John C Byrd; Michael R Grever; Manisha H Shah Journal: Invest New Drugs Date: 2010-10-12 Impact factor: 3.850
Authors: Yulan Cheng; Zhe Jin; Rachana Agarwal; Ke Ma; Jian Yang; Soibrahim Ibrahim; Alexandru V Olaru; Stefan David; Hassan Ashktorab; Duane T Smoot; Mark D Duncan; David F Hutcheon; John M Abraham; Stephen J Meltzer; Yuriko Mori Journal: Lab Invest Date: 2012-04-09 Impact factor: 5.662